#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	3196	16S	1529	1529	99.87	16S.l15.c30.ctg.1	2257	414.7	0	.	n	.	0	A69G	SNP	69	69	A	376	376	G	412	G,A	265,80	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	3196	16S	1529	1529	99.87	16S.l15.c30.ctg.1	2257	414.7	0	.	n	.	0	C1450T	SNP	1450	1450	C	1757	1757	T	441	T,C	378,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	3196	16S	1529	1529	99.87	16S.l15.c30.ctg.1	2257	414.7	1	SNP	n	C1184T	0	.	.	1184	1184	C	1491	1491	C	511	C	415	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5410	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3967	408.1	0	.	n	.	0	G1337A	SNP	1337	1337	G	1918	1918	A	446	A,G	384,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5410	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3967	408.1	0	.	n	.	0	T1971C	SNP	1971	1971	T	2552	2552	C	489	C	397	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5410	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3967	408.1	1	SNP	n	A2045G	0	.	.	2045	2045	A	2626	2626	A	526	A,T	426,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5410	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3967	408.1	1	SNP	n	C2597T	0	.	.	2597	2597	C	3178	3178	C	448	C,T	352,2	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_X_01360c	folP.WHO_X_01360c	1	1	539	464	folP	852	852	99.88	folP.l15.c4.ctg.1	1952	71.3	0	.	p	.	0	E151K	NONSYN	451	453	GAA	952	954	AAA	92;93;94	A;A;A	80;81;81	.	.
folP.WHO_X_01360c	folP.WHO_X_01360c	1	1	539	464	folP	852	852	99.88	folP.l15.c4.ctg.1	1952	71.3	1	SNP	p	R228S	1	.	.	682	684	AGC	1183	1185	AGC	100;100;101	A;G;C	75;78;77	folP.WHO_X_01360c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1082	gyrA	2751	2751	100.0	gyrA.l6.c4.ctg.1	3660	88.2	1	SNP	p	S91F	0	.	.	271	273	TCC	747	749	TCC	88;89;90	T;C;C	75;75;77	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1082	gyrA	2751	2751	100.0	gyrA.l6.c4.ctg.1	3660	88.2	1	SNP	p	D95G	0	.	.	283	285	GAC	759	761	GAC	90;90;90	G,T;A;C	74,1;74;76	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1082	gyrA	2751	2751	100.0	gyrA.l6.c4.ctg.1	3660	88.2	1	SNP	p	D95N	0	.	.	283	285	GAC	759	761	GAC	90;90;90	G,T;A;C	74,1;74;76	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	27	532	mtrR	633	633	100.0	mtrR.l6.c17.ctg.1	1621	95.8	1	SNP	p	G45D	0	.	.	133	135	GGC	752	754	GGC	156;156;156	G;G;C	125;125;127	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	278	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1267	65.0	0	.	n	.	0	A197.	DEL	197	197	A	674	674	A	134	A	109	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	1096	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3330	98.1	1	SNP	p	D86N	0	.	.	256	258	GAC	821	823	GAC	115;116;116	G;A,T;C	93;91,1;95	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	1096	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3330	98.1	1	SNP	p	S87R	0	.	.	259	261	AGT	824	826	AGT	117;118;118	A;G;T	86;94;95	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	1096	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3330	98.1	1	SNP	p	S87I	0	.	.	259	261	AGT	824	826	AGT	117;118;118	A;G;T	86;94;95	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	1096	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3330	98.1	1	SNP	p	S87W	0	.	.	259	261	AGT	824	826	AGT	117;118;118	A;G;T	86;94;95	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	1096	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3330	98.1	1	SNP	p	S88P	0	.	.	262	264	TCC	827	829	TCC	119;120;120	T;C;C	92;91;98	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	888	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2769	94.7	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1560	1562	GGC	108;108;107	G;G,C;C	91;88,1;90	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	914	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2592	105.2	1	SNP	p	A311V	0	.	.	931	933	GCA	1375	1377	GCA	143;146;146	G;C;A,C	121;123;119,1	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	914	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2592	105.2	1	SNP	p	I312M	0	.	.	934	936	ATC	1378	1380	ATC	146;146;147	A;T;C	124;117;124	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	914	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2592	105.2	1	SNP	p	V316P	0	.	.	946	948	GTG	1390	1392	GTG	142;142;143	G;T;G	118;115;119	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	914	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2592	105.2	1	SNP	p	V316T	0	.	.	946	948	GTG	1390	1392	GTG	142;142;143	G;T;G	118;115;119	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	914	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2592	105.2	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1894	1896	ACC	94;94;94	A;C,A;C	83;79,1;83	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	914	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2592	105.2	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1948	1950	GCG	92;92;90	G;C,G;G	78;74,1;73	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	914	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2592	105.2	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1948	1950	GCG	92;92;90	G;C,G;G	78;74,1;73	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	914	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2592	105.2	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2071	2073	GGC	108;108;108	G;G,C;C	86;88,1;90	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	914	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2592	105.2	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2080	2082	GGC	106;107;107	G,A,C;G;C,G	84,2,1;90;88,2	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	914	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2592	105.2	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2098	2100	CTG	110;109;108	C;T;G,T	89;89;82,2	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1126	ponA	2397	2397	100.0	ponA.l6.c4.ctg.1	3438	98.1	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1762	1764	CCG	97;97;97	C;C;G	73;75;76	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	594	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2213	80.6	0	.	p	.	0	M83fs	FSHIFT	247	247	A	761	761	C	86	C	69	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	82	porB1a	984	297	90.37	porB1a.l6.c30.ctg.1	1185	17.4	0	.	p	.	0	H217N	NONSYN	649	651	CAT	911	913	AAT	11;11;11	A;A;T	10;11;11	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	82	porB1a	984	297	90.37	porB1a.l6.c30.ctg.1	1185	17.4	0	.	p	.	0	D218N	NONSYN	652	654	GAT	914	916	AAT	11;11;11	A;A;T	10;11;10	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	82	porB1a	984	297	90.37	porB1a.l6.c30.ctg.1	1185	17.4	0	.	p	.	0	V226A	NONSYN	676	678	GTA	938	940	GCA	10;10;10	G;C;A	10;10;10	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	82	porB1a	984	297	90.37	porB1a.l6.c30.ctg.1	1185	17.4	0	.	p	.	0	.	MULTIPLE	700	702	ACT	961	963	GTA	9;9;9	G;T;A	9;9;9	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	82	porB1a	984	297	90.37	porB1a.l6.c30.ctg.1	1185	17.4	0	.	p	.	0	S236N	NONSYN	706	708	AGC	967	969	AAC	9;9;9	A;A;C	9;9;9	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	82	porB1a	984	297	90.37	porB1a.l6.c30.ctg.1	1185	17.4	0	.	p	.	0	.	MULTIPLE	709	711	AAC	971	975	TGGCG	9;9;9;9;9	T;G;G;C;G	9;9;9;9;9	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	82	porB1a	984	297	90.37	porB1a.l6.c30.ctg.1	1185	17.4	0	.	p	.	0	D238A	NONSYN	712	714	GAT	977	979	GCT	9;9;9	G;C;T	9;9;9	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	82	porB1a	984	297	90.37	porB1a.l6.c30.ctg.1	1185	17.4	0	.	p	.	0	V258L	NONSYN	772	774	GTA	1037	1039	TTA	9;9;9	T;T;A	9;9;9	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	82	porB1a	984	297	90.37	porB1a.l6.c30.ctg.1	1185	17.4	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	1082	1084	CAT	11;11;11	C;A;T	8;8;8	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	82	porB1a	984	297	90.37	porB1a.l6.c30.ctg.1	1185	17.4	0	.	p	.	0	D274S	NONSYN	820	822	GAT	1085	1087	AGT	11;12;12	A;G;T	8;8;8	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	82	porB1a	984	297	90.37	porB1a.l6.c30.ctg.1	1185	17.4	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	1094	1096	TAC	12;12;12	T;A;C	8;8;8	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	666	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	1774	109.9	0	.	p	.	0	N38E	NONSYN	112	114	AAT	500	502	GAA	118;120;120	G;A;A	97;97;100	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	666	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	1774	109.9	0	.	p	.	0	N134D	NONSYN	400	402	AAT	788	790	GAT	154;153;155	G;A;T	126;119;127	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	666	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	1774	109.9	0	.	p	.	0	P175S	NONSYN	523	525	CCA	911	913	TCA	145;145;145	T;C;A	117;121;120	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	666	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	1774	109.9	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1040	1042	GTC	146;146;147	G,T;T;C	118,1;122;120	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	666	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	1774	109.9	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1370	1372	GCA	149;150;149	G;C,T;A	120;118,1;117	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	666	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	1774	109.9	1	SNP	p	G120K	1	.	.	358	360	AAG	746	748	AAG	148;147;146	A;A;G,T	117;116;116,2	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	666	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	1774	109.9	1	SNP	p	D121N	0	.	.	361	363	GAC	749	751	GAC	146;149;148	G;A;C	116;121;116	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	666	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	1774	109.9	1	SNP	p	A121D	1	.	.	361	363	GAC	749	751	GAC	146;149;148	G;A;C	116;121;116	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	2208	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5073	129.7	1	SNP	p	H553N	1	H553N	NONSYN	1657	1659	CAT	2141	2143	AAT	124;126;124	A;A;T	97;95;95	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	320	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1307	72.4	1	SNP	p	V57M	1	.	.	169	171	ATG	723	725	ATG	131;131;131	A;T;G	106;105;100	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
